Matt O'Brien
Stock Analyst at Piper Sandler
(2.09)
# 2,974
Out of 5,005 analysts
185
Total ratings
39.61%
Success rate
-6.37%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SI Shoulder Innovations | Initiates: Overweight | $18 | $12.19 | +47.66% | 1 | Aug 25, 2025 | |
| CARL Carlsmed | Initiates: Overweight | $18 | $12.97 | +38.78% | 1 | Aug 18, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $80 → $55 | $35.97 | +52.91% | 4 | Aug 7, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $30 → $14 | $14.71 | -4.83% | 9 | Aug 7, 2025 | |
| DXCM DexCom | Maintains: Overweight | $90 → $100 | $67.05 | +49.14% | 12 | Jul 31, 2025 | |
| CNMD CONMED | Maintains: Overweight | $80 → $68 | $48.13 | +41.28% | 13 | Jul 31, 2025 | |
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $115.69 | +25.33% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $60.48 | +32.28% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $8.71 | +37.77% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $18.77 | +59.83% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 → $15 | $13.96 | +7.45% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $87.41 | +88.77% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $24.82 | +8.78% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $2 | $1.56 | +28.21% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.29 | +6.38% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $130.90 | +6.95% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $22.26 | +16.80% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $309.12 | +0.29% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $256.06 | +28.88% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $34.63 | +44.38% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $27.14 | -41.05% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $97.32 | +18.17% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $5.54 | +116.61% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $370.50 | +13.36% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $105.04 | +33.28% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $97.70 | -7.88% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $14.50 | +72.41% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.10 | +42.86% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $2.39 | +88.28% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $100.78 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.71 | +453.51% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $70.46 | +54.34% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $1.47 | +1,136.73% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $23.86 | +235.29% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.85 | +211.69% | 1 | Jun 24, 2020 |
Shoulder Innovations
Aug 25, 2025
Initiates: Overweight
Price Target: $18
Current: $12.19
Upside: +47.66%
Carlsmed
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $12.97
Upside: +38.78%
PROCEPT BioRobotics
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $55
Current: $35.97
Upside: +52.91%
Tandem Diabetes Care
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $14.71
Upside: -4.83%
DexCom
Jul 31, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $67.05
Upside: +49.14%
CONMED
Jul 31, 2025
Maintains: Overweight
Price Target: $80 → $68
Current: $48.13
Upside: +41.28%
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $115.69
Upside: +25.33%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $60.48
Upside: +32.28%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $8.71
Upside: +37.77%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $18.77
Upside: +59.83%
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $13.96
Upside: +7.45%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $87.41
Upside: +88.77%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $24.82
Upside: +8.78%
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.56
Upside: +28.21%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.29
Upside: +6.38%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $130.90
Upside: +6.95%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $22.26
Upside: +16.80%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $309.12
Upside: +0.29%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $256.06
Upside: +28.88%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $34.63
Upside: +44.38%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $27.14
Upside: -41.05%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $97.32
Upside: +18.17%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $5.54
Upside: +116.61%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $370.50
Upside: +13.36%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $105.04
Upside: +33.28%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $97.70
Upside: -7.88%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $14.50
Upside: +72.41%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.10
Upside: +42.86%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $2.39
Upside: +88.28%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $100.78
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.71
Upside: +453.51%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $70.46
Upside: +54.34%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $1.47
Upside: +1,136.73%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $23.86
Upside: +235.29%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $3.85
Upside: +211.69%